Properties
What is it?
International Name - HEXESTROL Clinical-Pharmacological Group: Estrogen analog - non-steroidal structure Composition and Dosage Form: Oily solution for injection 2%: 1 ml in ampoule, 10 pcs. in a pack. 1 ml. Hexestrol ....... 20 mg Indications: Ovarian hypofunction (amenorrhea, hypomenorrhea, oligomenorrhea, dysmenorrhea), infertility, vaginitis (in girls and elderly women), genital hypoplasia, sexual infantilism, secondary estrogen deficiency, post-castration and climacteric disorders, weakness of labor, virile hypertrichosis in women; necessity of lactation suppression. Breast cancer, prostate hypertrophy, prostate cancer (in complex therapy – surgical treatment, radiation therapy) – 2% solution. Dosage and Administration: For genital hypoplasia, congenital amenorrhea, and underdeveloped uterus, administer intramuscularly 1–2 mg or orally 2 mg 1–2 times a day for 4–6 weeks or longer. After effect, progesterone 5 mg intramuscularly daily or pregnin (10 mg 3 times a day orally) for 6–8 days. If necessary, the course of hormone therapy is repeated. For secondary amenorrhea, administer 1–2 mg daily for 15–20 days, followed by progesterone or pregnin at the indicated dose for 6–8 days. For hypo- and oligomenorrhea – intramuscularly or orally 1 mg daily or every other day during the first intermenstrual period; for infertility due to uterine underdevelopment – 1 mg intramuscularly or 1–2 mg orally for the first 7–8 days after menstruation; for climacteric disorders – 0.5–1 mg orally. To reduce lactation after childbirth, administer 1 mg orally twice a day or 1 ml of 0.1% solution intramuscularly once a day for 2 days; for complete lactation suppression – 2–3 mg daily, 1 ml of 0.1% solution twice a day for 5–7 days. For breast cancer in women over 60 years of age, administer the 2% solution intramuscularly daily, starting with 20 mg/day, then gradually increasing the daily dose up to 100 mg; select the optimal dose, which is administered for a long time. For prostate hypertrophy – 40 mg intramuscularly daily for 30 days; conduct 2–3 more courses of 20 days each year with 2–3 month intervals. For prostate cancer – 60–80 mg intramuscularly daily for 2 months, then 10–20 mg daily, intramuscularly or orally. The total dose and duration of treatment depend on the degree of prostate changes, the presence or absence of metastases, the degree of feminization, and the general condition. Maximum dose in adults: intramuscularly – single dose 2 mg (2 ml of 0.1% solution); daily – 3 mg. For the treatment of malignant tumors, maximum single dose – 60 mg (3 ml of 2% solution); maximum daily dose – 100 mg (5 ml of 2% solution). Contraindications: Hypersensitivity, pregnancy, estrogen-dependent malignant tumors or suspicion thereof, unusual or undiagnosed genital or uterine bleeding, thrombophlebitis or thromboembolic disease in the active phase (except for the treatment of breast and prostate cancer). Side Effects: In women: pain, increased sensitivity and enlargement of the mammary glands, amenorrhea, bleeding, menorrhagia, "sticky" vaginal discharge between periods, breast tumors, increased libido. In men: pain and increased sensitivity of the mammary glands, gynecomastia, decreased libido. Peripheral edema, bile duct obstruction, hepatitis, pancreatitis. Intestinal or biliary colic, meteorism, anorexia, nausea, diarrhea, dizziness, headache (including migraine), intolerance to contact lenses, vomiting (more often of central origin, more often when high doses are prescribed). During the treatment of prostate and breast cancer (additionally): thromboembolism, thrombosis.